A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.

Keisuke HorikoshiNorihiko SakaiNaoki YamamotoHisayuki OguraKoichi SatoTaro MiyagawaShinji KitajimaTadashi ToyamaAkinori HaraYasunori IwataMiho ShimizuKengo FuruichiTakashi Wada

Published in: BMC nephrology (2020)

This might be a case wherein RANKL inhibition is associated with the pathogenesis of MCD. Further studies will be needed to elucidate the causal relationship of RANK-RANKL signaling to the pathogenesis of MCD.

Keyphrases

nuclear factor
monoclonal antibody
toll like receptor
inflammatory response
case control
binding protein